+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Leukemia Therapeutics Market Size, Share & Trends Analysis Report by Type of Leukemia (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)), Treatment Type, Distribution Channel and Region with Growth Forecasts, 2025-2033

  • PDF Icon

    Report

  • 150 Pages
  • November 2025
  • Region: Global
  • Grand View Research
  • ID: 6214588
REQUEST CUSTOMIZATION
Description Jump to:
The global leukemia therapeutics market size was estimated at USD 18.90 billion in 2024 and is projected to reach USD 36.02 billion by 2033, growing at a CAGR of 7.43% from 2025 to 2033. The market is expanding due to a rising global prevalence of acute and chronic leukemia across all age groups.

The growing adoption of precision oncology is enabling treatments tailored to genetic and molecular profiles, thereby improving patient outcomes. Advancements in diagnostic technologies are enabling earlier detection, which supports higher rates of treatment initiation. Pharmaceutical innovation in targeted therapies and immunotherapies is accelerating clinical adoption and shifting treatment standards. For instance, in April 2025, Frontiers in Medicine published a global burden study which reported that in 2021, there were approximately 461,422.7 leukemia incident cases, projected to reach 509,737.3 by 2031, and around 320,283.6 deaths in 2021 expected to rise to 344,694.3 by 2031, while DALYs declined from 10,982,836.2 to 10,785,356.1 during the same period.

Increasing survival rates are creating a larger population requiring long-term and sequential therapy. Strong R&D momentum supported by active clinical trials is introducing new therapeutic classes with improved efficacy. The commercial availability of combination regimens is further driving prescription volume and increasing therapy value.

The rapid penetration of targeted small-molecule drugs is transforming treatment strategies for AML, CLL, and ALL, delivering high response rates with manageable safety profiles. Continuous progress in kinase inhibitors, BCL-2 inhibitors, and monoclonal antibodies is driving a shift away from traditional chemotherapy. CAR-T therapies are gaining adoption due to their ability to achieve durable remission in patients with relapsed or refractory disease. For instance, in March 2025, Therapeutic Advances in Hematology reported a phase I trial in which 7 of 10 AML patients treated with anti-CLL-1 CAR-T achieved complete remission or CRi. All six who later underwent stem cell transplantation were alive at follow-up. At the same time, another trial showed three complete remissions among six patients receiving anti-CD38 CAR-T, with only grade 1-2 CRS and no ICANS events. Growing access to stem cell transplantation, wider use of oral regimens, and active label expansion strategies are strengthening long-term market growth.

Global Leukemia Therapeutics Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the global leukemia therapeutics market report based on type of leukemia, treatment type, distribution channel, and region:

Type of Leukemia Outlook (Revenue, USD Million, 2021-2033)

  • Chronic Myeloid Leukemia (CML)
  • Chronic Lymphocytic Leukemia (CLL)
  • Acute Lymphocytic Leukemia (ALL)
  • Acute Myeloid Leukemia (AML)
  • Others

Treatment Type Outlook (Revenue, USD Million, 2021-2033)

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy
  • Others

Distribution ChannelOutlook (Revenue, USD Million, 2021-2033)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

Regional Outlook (Revenue, USD Million, 2021-2033)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type of Leukemia
1.2.2. Treatment Type
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Leukemia Therapeutics Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Leukemia Therapeutics Market: Type of Leukemia Business Analysis
4.1. Type of Leukemia Market Share, 2024 & 2033
4.2. Type of Leukemia Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type of Leukemia, 2021 to 2033 (USD Million)
4.4. Chronic Myeloid Leukemia (CML)
4.4.1. Chronic Myeloid Leukemia (CML) Market, 2021-2033 (USD Million)
4.5. Chronic Lymphocytic Leukemia (CLL)
4.5.1. Chronic Lymphocytic Leukemia (CLL) Market, 2021-2033 (USD Million)
4.6. Acute Lymphocytic Leukemia (ALL)
4.6.1. Acute Lymphocytic Leukemia (ALL) Market, 2021-2033 (USD Million)
4.7. Acute Myeloid Leukemia (AML)
4.7.1. Acute Myeloid Leukemia (AML) Market, 2021-2033 (USD Million)
4.8. Others
4.8.1. Others Market, 2021-2033 (USD Million)
Chapter 5. Leukemia Therapeutics Market: Treatment Type Business Analysis
5.1. Treatment Type Market Share, 2024 & 2033
5.2. Treatment Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by treatment type, 2021 to 2033 (USD Million)
5.4. Chemotherapy
5.4.1. Chemotherapy Market, 2021-2033 (USD Million)
5.5. Targeted Therapy
5.5.1. Targeted Therapy Market, 2021-2033 (USD Million)
5.6. Immunotherapy
5.6.1. Immunotherapy Market, 2021-2033 (USD Million)
5.7. Others
5.7.1. Others Market, 2021-2033 (USD Million)
Chapter 6. Leukemia Therapeutics Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by distribution channel, 2021 to 2033 (USD Million)
6.4. Hospital Pharmacy
6.4.1. Hospital Pharmacy Market, 2021-2033 (USD Million)
6.5. Retail Pharmacy
6.5.1. Retail Pharmacy Market, 2021-2033 (USD Million)
6.6. Others
6.6.1. Others Market, 2021-2033 (USD Million)
Chapter 7. Leukemia Therapeutics Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
7.4.1. North America Leukemia Therapeutics Market Estimates and Forecasts, By Country, 2021-2033 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Treatment Type Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Framework
7.4.2.5. U.S. Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Treatment Type Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Framework
7.4.3.5. U.S. Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Treatment Type Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Framework
7.4.4.5. Mexico Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5. Europe
7.5.1. Europe Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Treatment Type Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Framework
7.5.2.5. UK Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Treatment Type Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Framework
7.5.3.5. Germany Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Treatment Type Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Framework
7.5.4.5. France Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Treatment Type Disease Prevalence
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Framework
7.5.5.5. Italy Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Treatment Type Disease Prevalence
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Framework
7.5.6.5. Spain Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Treatment Type Disease Prevalence
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Framework
7.5.7.5. Denmark Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Treatment Type Disease Prevalence
7.5.8.3. Regulatory Framework
7.5.8.4. Reimbursement Framework
7.5.8.5. Sweden Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Treatment Type Disease Prevalence
7.5.9.3. Regulatory Framework
7.5.9.4. Reimbursement Framework
7.5.9.5. Norway Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6. Asia-Pacific
7.6.1. Asia-Pacific Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Treatment Type Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Framework
7.6.2.5. Japan Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Treatment Type Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Framework
7.6.3.5. China Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Treatment Type Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Framework
7.6.4.5. India Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Treatment Type Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Framework
7.6.5.5. Australia Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Treatment Type Disease Prevalence
7.6.6.3. Regulatory Framework
7.6.6.4. Reimbursement Framework
7.6.6.5. South Korea Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Treatment Type Disease Prevalence
7.6.7.3. Regulatory Framework
7.6.7.4. Reimbursement Framework
7.6.7.5. Thailand Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7. Latin America
7.7.1. Latin America Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Treatment Type Disease Prevalence
7.7.2.3. Regulatory Framework
7.7.2.4. Reimbursement Framework
7.7.2.5. Japan Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Treatment Type Disease Prevalence
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Framework
7.7.3.5. China Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Treatment Type Disease Prevalence
7.8.2.3. Regulatory Framework
7.8.2.4. Reimbursement Framework
7.8.2.5. South Africa Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Treatment Type Disease Prevalence
7.8.3.3. Regulatory Framework
7.8.3.4. Reimbursement Framework
7.8.3.5. Saudi Arabia Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Treatment Type Disease Prevalence
7.8.4.3. Regulatory Framework
7.8.4.4. Reimbursement Framework
7.8.4.5. UAE Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Treatment Type Disease Prevalence
7.8.5.3. Regulatory Framework
7.8.5.4. Reimbursement Framework
7.8.5.5. Kuwait Leukemia Therapeutics Market Estimates and Forecasts, 2021-2033 (USD Million)
Chapter 8. Competitive Landscape
8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
8.5.1. Pfizer Inc.
8.5.1.1. Overview
8.5.1.2. Financial Performance
8.5.1.3. Product Benchmarking
8.5.1.4. Strategic Initiatives
8.5.2. Novartis
8.5.2.1. Overview
8.5.2.2. Financial Performance
8.5.2.3. Product Benchmarking
8.5.2.4. Strategic Initiatives
8.5.3. Lupin Ltd.
8.5.3.1. Overview
8.5.3.2. Financial Performance
8.5.3.3. Product Benchmarking
8.5.3.4. Strategic Initiatives
8.5.4. Amgen Inc.
8.5.4.1. Overview
8.5.4.2. Financial Performance
8.5.4.3. Product Benchmarking
8.5.4.4. Strategic Initiatives
8.5.5. AbbVie
8.5.5.1. Overview
8.5.5.2. Financial Performance
8.5.5.3. Product Benchmarking
8.5.5.4. Strategic Initiatives
8.5.6. Johnson & Johnson Services, Inc.
8.5.6.1. Overview
8.5.6.2. Financial Performance
8.5.6.3. Product Benchmarking
8.5.6.4. Strategic Initiatives
8.5.7. Bristol-Myers Squibb
8.5.7.1. Overview
8.5.7.2. Financial Performance
8.5.7.3. Product Benchmarking
8.5.7.4. Strategic Initiatives
8.5.8. F. Hoffmann-La Roche
8.5.8.1. Overview
8.5.8.2. Financial Performance
8.5.8.3. Product Benchmarking
8.5.8.4. Strategic Initiatives
8.5.9. Takeda Pharmaceutical Co Ltd
8.5.9.1. Overview
8.5.9.2. Financial Performance
8.5.9.3. Product Benchmarking
8.5.9.4. Strategic Initiatives
8.5.10. Sanofi/ Genzyme Corporation
8.5.10.1. Overview
8.5.10.2. Financial Performance
8.5.10.3. Product Benchmarking
8.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global leukemia therapeutics market, by region, 2021-2033 (USD Million)
Table 4 Global leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 5 Global leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 6 Global leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 7 North America leukemia therapeutics market, by country, 2021-2033 (USD Million)
Table 8 North America leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 9 North America leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 10 North America leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 11 U.S. leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 12 U.S. leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 13 U.S. leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 14 Canada leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 15 Canada leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 16 Canada leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 17 Mexico leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 18 Mexico leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 19 Mexico leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 20 Europe leukemia therapeutics market, by country, 2021-2033 (USD Million)
Table 21 Europe leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 22 Europe leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 23 Europe leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 24 UK leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 25 UK leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 26 UK leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 27 Germany leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 28 Germany leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 29 Germany leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 30 France leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 31 France leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 32 France leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 33 Italy leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 34 Italy leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 35 Italy leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 36 Spain leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 37 Spain leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 38 Spain leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 39 Norway leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 40 Norway leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 41 Norway leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 42 Denmark leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 43 Denmark leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 44 Denmark leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 45 Sweden leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 46 Sweden leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 47 Sweden leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 48 Asia-Pacific leukemia therapeutics market, by country, 2021-2033 (USD Million)
Table 49 Asia-Pacific leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 50 Asia-Pacific leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 51 Asia-Pacific leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 52 Million)
Table 53 Japan leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 54 Japan leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 55 Japan leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 56 China leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 57 China leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 58 China leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 59 India leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 60 India leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 61 India leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 62 Australia leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 63 Australia leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 64 Australia leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 65 South Korea leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 66 South Korea leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 67 South Korea leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 68 Thailand leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 69 Thailand leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 70 Thailand leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 71 Latin America leukemia therapeutics market, by country, 2021-2033 (USD Million)
Table 72 Latin America leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 73 Latin America leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 74 Latin America leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 75 Brazil leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 76 Brazil leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 77 Brazil leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 78 Argentina leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 79 Argentina leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 80 Argentina leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 81 Middle East & Africa Leukemia therapeutics market, by country, 2021-2033 (USD Million)
Table 82 Middle East & Africa leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 83 Middle East & Africa leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 84 Middle East & Africa leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 85 South Africa leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 86 South Africa leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 87 South Africa leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 88 Saudi Arabia leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 89 Saudi Arabia leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 90 Saudi Arabia leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 91 UAE leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 92 UAE leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 93 UAE leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
Table 94 Kuwait leukemia therapeutics market, by type of leukemia, 2021-2033 (USD Million)
Table 95 Kuwait leukemia therapeutics market, by treatment type, 2021-2033 (USD Million)
Table 96 Kuwait leukemia therapeutics market, by distribution channel, 2021-2033 (USD Million)
List of Figures
Figure 1 Leukemia therapeutics market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Leukemia therapeutics market dynamics
Figure 12 Leukemia therapeutics market: Porter’s five forces analysis
Figure 13 Leukemia therapeutics market: PESTLE analysis
Figure 14 Type of Leukemia market, 2021-2033 (USD Million)
Figure 15 Chronic Myeloid Leukemia (CML) market, 2021-2033 (USD Million)
Figure 16 Chronic Lymphocytic Leukemia (CLL) market, 2021-2033 (USD Million)
Figure 17 Acute Lymphocytic Leukemia (ALL) market, 2021-2033 (USD Million)
Figure 18 Acute Myeloid Leukemia (AML) market, 2021-2033 (USD Million)
Figure 19 Others market, 2021-2033 (USD Million)
Figure 20 Treatment Type market, 2021-2033 (USD Million)
Figure 21 Chemotherapy market, 2021-2033 (USD Million)
Figure 22 Targeted Therapy market, 2021-2033 (USD Million)
Figure 23 Immunotherapy market, 2021-2033 (USD Million)
Figure 24 Others market, 2021-2033 (USD Million)
Figure 25 Distribution Channel market, 2021-2033 (USD Million)
Figure 26 Hospital Pharmacy market, 2021-2033 (USD Million)
Figure 27 Retail Pharmacy market, 2021-2033 (USD Million)
Figure 28 Others market, 2021-2033 (USD Million)
Figure 29 Leukemia therapeutics market revenue, by region
Figure 30 Regional marketplace: Key takeaways
Figure 31 North America leukemia therapeutics market, 2021-2033 (USD Million)
Figure 32 U.S. country dynamics
Figure 33 U.S. leukemia therapeutics market, 2021-2033 (USD Million)
Figure 34 Canada country dynamics
Figure 35 Canada leukemia therapeutics market, 2021-2033 (USD Million)
Figure 36 Mexico country dynamics
Figure 37 Mexico leukemia therapeutics market, 2021-2033 (USD Million)
Figure 38 Europe leukemia therapeutics market, 2021-2033 (USD Million)
Figure 39 UK country dynamics
Figure 40 UK leukemia therapeutics market, 2021-2033 (USD Million)
Figure 41 Germany country dynamics
Figure 42 Germany leukemia therapeutics market, 2021-2033 (USD Million)
Figure 43 France country dynamics
Figure 44 France leukemia therapeutics market, 2021-2033 (USD Million)
Figure 45 Italy country dynamics
Figure 46 Italy leukemia therapeutics market, 2021-2033 (USD Million)
Figure 47 Spain country dynamics
Figure 48 Spain leukemia therapeutics market, 2021-2033 (USD Million)
Figure 49 Norway country dynamics
Figure 50 Norway leukemia therapeutics market, 2021-2033 (USD Million)
Figure 51 Sweden country dynamics
Figure 52 Sweden leukemia therapeutics market, 2021-2033 (USD Million)
Figure 53 Denmark country dynamics
Figure 54 Denmark leukemia therapeutics market, 2021-2033 (USD Million)
Figure 55 Asia-Pacific leukemia therapeutics market, 2021-2033 (USD Million)
Figure 56 Japan country dynamics
Figure 57 Japan leukemia therapeutics market, 2021-2033 (USD Million)
Figure 58 China country dynamics
Figure 59 China leukemia therapeutics market, 2021-2033 (USD Million)
Figure 60 India country dynamics
Figure 61 India leukemia therapeutics market, 2021-2033 (USD Million)
Figure 62 Australia country dynamics
Figure 63 Australia leukemia therapeutics market, 2021-2033 (USD Million)
Figure 64 South Korea country dynamics
Figure 65 South Korea leukemia therapeutics market, 2021-2033 (USD Million)
Figure 66 Thailand country dynamics
Figure 67 Thailand leukemia therapeutics market, 2021-2033 (USD Million)
Figure 68 Latin America leukemia therapeutics market, 2021-2033 (USD Million)
Figure 69 Brazil country dynamics
Figure 70 Brazil leukemia therapeutics market, 2021-2033 (USD Million)
Figure 71 Argentina country dynamics
Figure 72 Argentina leukemia therapeutics market, 2021-2033 (USD Million)
Figure 73 MEA leukemia therapeutics market, 2021-2033 (USD Million)
Figure 74 South Africa country dynamics
Figure 75 South Africa leukemia therapeutics market, 2021-2033 (USD Million)
Figure 76 Saudi Arabia country dynamics
Figure 77 Saudi Arabia leukemia therapeutics market, 2021-2033 (USD Million)
Figure 78 UAE country dynamics
Figure 79 UAE leukemia therapeutics market, 2021-2033 (USD Million)
Figure 80 Kuwait country dynamics
Figure 81 Kuwait leukemia therapeutics market, 2021-2033 (USD Million)
Figure 82 Company categorization
Figure 83 Company market position analysis
Figure 84 Strategic framework

Companies Mentioned

The key companies profiled in this Leukemia Therapeutics market report include:
  • Pfizer Inc.
  • Novartis
  • Lupin Ltd.
  • Amgen Inc.
  • AbbVie
  • Johnson & Johnson Services, Inc.
  • Bristol-Myers Squibb
  • F. Hoffmann-La Roche
  • Takeda Pharmaceutical Co Ltd
  • Sanofi/ Genzyme Corporation

Table Information

Report AttributeDetails
No. of Pages150
PublishedNovember 2025
Forecast Period2024 - 2033
Estimated Market Value ( USD ) in 2024 $ 18.9 Billion
Forecasted Market Value ( USD ) by 2033 $ 36.02 Billion
Compound Annual Growth Rate7.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

U.S. Leukemia Therapeutics Market Size, Share & Trends Analysis Report by Type (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)), Treatment, Distribution Channels with Growth Forecasts, 2025-2033 - Product Image

U.S. Leukemia Therapeutics Market Size, Share & Trends Analysis Report by Type (Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL)), Treatment, Distribution Channels with Growth Forecasts, 2025-2033

  • Report
  • 150 Pages
  • United States
From
Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2025-2033 - Product Image

Acute Myeloid Leukemia Therapeutics Market Report by Treatment Type, Drug Type, Route of Administration, and Region 2025-2033

  • Report
  • 144 Pages
  • Global
From
Global Acute Lymphoblastic Leukemia Therapeutics Market: Focus on Cell Type, Therapy Type, and Over 10 Countries' Data - Analysis and Forecast, 2024-2033 - Product Image

Global Acute Lymphoblastic Leukemia Therapeutics Market: Focus on Cell Type, Therapy Type, and Over 10 Countries' Data - Analysis and Forecast, 2024-2033

  • Report
  • 134 Pages
  • Global
From
Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics: Market Share, and Growth Analysis by Product Type (Chemotherapy, Targeted Therapy, Immunotherapy), Application, End User, Technology - Product Image

Acute Lymphocytic-Lymphoblastic Leukemia Therapeutics: Market Share, and Growth Analysis by Product Type (Chemotherapy, Targeted Therapy, Immunotherapy), Application, End User, Technology

  • Report
  • 150 Pages
  • Global
From
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Report and Forecast 2025-2034 - Product Image

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.